TNFRSF18 and cancer: Although the clinical development of GITR-specific antibodies is limited to date [2], the aforementioned findings provide further support for the continued development of agonistic anti-GITR mAbs as an immunotherapeutic strategy for cancer and antibodies from GITR Inc., Merck, Agenus, and others are in preclinical and early clinical development [2].